Replies to post #18603 on GTC Biotherapeutics (fka GTCB)

[biopearl]

Vin, I have always admired and valued Dew's insights and ideas. He was the first I believe to point out that something was not right in the relationship between LEO and GTCB. He suspected it was a safety or efficacy issue but it may turn out to be something else, but what we don't know yet. bp

[DewDiligence]

As you recall Dew has claimed repeatedly that GTCB and LEO lied about rATIII in the past.

There you go again, Vinny!

Actually, I’m not aware of any statement from Leo giving the reason they abandoned ATryn. All I’ve seen is a statement from GTC that Leo abandoned ATryn due to a “portfolio reprioritization.”

Hence, I’m not sure why you persist in attributing to me the notion that Leo (as opposed to GTC) has been lying about ATryn.